Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Previous studies have investigated the potential atherogenicity and thrombogenicity of triglyceride-rich lipoprotein (TRL) remnants by isolating them from plasma within a remnant-like particle (RLP) fraction, using an immunoaffinity gel containing specific anti-apoB-100 and anti-apoA-I antibodies. In order to characterize lipoproteins in this RLP fraction and to determine to what extent their composition varies from one individual to another, we have used automated gel filtration chromatography to determine the size heterogeneity of RLP isolated from normolipidemic control subjects (n = 8), and from type III (n = 6) and type IV (n = 9) hyperlipoproteinemic patients, who by selection had similarly elevated levels of plasma triglyceride (406 +/- 43 and 397 +/- 35 mg/dl, respectively). Plasma RLP triglyceride, cholesterol, apoB, apoC-III, and apoE concentrations were elevated 2- to 6-fold (P < 0. 05) in hyperlipoproteinemic patients compared to controls. RLP fractions of type III patients were enriched in cholesterol and apoE compared to those of type IV patients, and RLP of type IV patients were enriched in triglyceride and apoC-III relative to those of normolipidemic subjects. In normolipidemic subjects, the majority of RLP had a size similar to LDL or HDL. The RLP of hyperlipoproteinemic patients were, however, larger and were similar in size to TRL, or were intermediate in size (i.e., ISL) between that of TRL and LDL. Compared to controls, ISL in the RLP fraction of type III patients were enriched in apoE relative to apoC-III, whereas in type IV patients they were enriched in apoC-III relative to apoE. These results demonstrate that: 1) RLP are heterogeneous in size and composition in both normolipidemic and hypertriglyceridemic subjects, and 2) the apoE and apoC-III composition of RLP is different in type III compared to type IV hyperlipoproteinemic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Remnant lipoproteins are enriched in cholesterol (both free and esterified) and are depleted in apoC proteins and enriched in apoE (Figure 2).5–7”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several factors, including activating or inhibitory apolipoproteins (apoCII and apoCIII, respectively) on the TRL surface, and LpL availability, influence residence time in the circulation and the potential entry and retention of remnants within the arterial subendothelial space.5”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Remnant particles may contain up to four-fold greater cholesterol content per particle than LDL.”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“VLDL and remnants are also enriched in apoE and apoCIII, both implicated in binding and retention in the artery wall.5,71,125”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“The longer a remnant remains in the circulation, the more it becomes enriched with CE; the cholesterol content in these end-product remnants can exceed 7500 molecules per particle (vs. 2000–2700 in LDL).”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic Basis of Inherited Disease.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-503_7 · Cited by 7,786
The Metabolic Basis of Inherited Diseases
Winkelmann, R. K. (1972) · Archives of Dermatology · doi:10.1001/archderm.1972.01620110090032 · Cited by 1,769
Warnick, G. R., & Albers, J. J. (1978) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41577-9 · Cited by 1,250
Weisgraber, K. H., Innerarity, T. L., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34954-8 · Cited by 673
Havel, R. J., Kane, J. P., & Kashyap, M. L. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107171 · Cited by 528
The Familial Hyperlipoproteinemias
Marion, M. S. (1975) · Cited by 528
Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein
Virgil Brown, W., & Baginsky, M. L. (1972) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(72)80149-9 · Cited by 491
Aalto-Setälä, K., Fisher, E. A., Chen, X., Chajek-Shaul, T., Hayek, T., Zechner, R., Walsh, A., Ramakrishnan, R., Ginsberg, H. N., & Breslow, J. L. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116066 · Cited by 450
Kowal, R. C., Herz, J., Weisgraber, K. H., Mahley, R. W., Brown, M. S., & Goldstein, J. L. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)87014-4 · Cited by 445
Nakajima, K., Saito, T., Tamura, A., Suzuki, M., Nakano, T., Adachi, M., Tanaka, A., Tada, N., Nakamura, H., Campos, E., et al. (1993) · Clinica Chimica Acta · doi:10.1016/0009-8981(93)90062-9 · Cited by 416
Self-citation
Research works printed but not linked: 3
- 8. Nakajima, K., M. Okazaki, A. Tanaka, C. R. Pullinger, T. Wang, T. Nakano, M. Adachi, and R. J. Havel. 1996. Separation and determination of remnant-like particles in human serum using monoclonal antibodies to apoB-100 and apo AI. J. Clin. Lig. Assay. 19: 177-183.
- 15. Sekihara, T., T. Nakano, and K. Nakajima. 1996. High postprandial plasma remnant-like particles-cholesterol in patients with coro-
- 19. McNamara, J. R., P. K. Shah, S. M. Nelson, K. Nakajima, P. W. F. Wilson, and E. J. Schaefer. 1996. Lipoprotein remnant cholesterol and triglyceride values in coronary cases and Framingham controls. Circulation. 94: I-94 (abstract).
Cited by
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
McNamara, J. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00484-6 · Cited by 278
Nakajima, K., Nakano, T., & Tanaka, A. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.12.013 · Cited by 208
Self-citationKawakami, A., Aikawa, M., Libby, P., Alcaide, P., Luscinskas, F. W., & Sacks, F. M. (2006) · Circulation · doi:10.1161/circulationaha.105.591743 · Cited by 206
Twickler, T. B., Dallinga-Thie, G. M., Cohn, J. S., & Chapman, M. J. (2004) · Circulation · doi:10.1161/01.cir.0000125278.58527.f3 · Cited by 201
Self-citationKarpe, F., Boquist, S., Tang, R., Bond, G. M., de Faire, U., & Hamsten, A. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32331-2 · Cited by 174
Postprandial lipoprotein metabolism: VLDL vs chylomicrons
Nakajima, K., Nakano, T., Tokita, Y., Nagamine, T., Inazu, A., Kobayashi, J., Mabuchi, H., Stanhope, K. L., Havel, P. J., Okazaki, M., et al. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.04.018 · Cited by 168
Self-citationCohn, J. S., Marcoux, C., & Davignon, J. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.10.2474 · Cited by 156
Self-citationRemnant Lipoproteins As Strong Key Particles to Atherogenesis
Fujioka, Y., & Ishikawa, Y. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e598 · Cited by 146
Schaefer, E. J., Audelin, M. C., McNamara, J. R., Shah, P. K., Tayler, T. D., Daly, J. A., Augustín, J., SEMAN, L. J., & Rubenstein, J. J. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02047-1 · Cited by 126
ANDO, M., SANAKA, T., & NIHEI, H. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v10102177 · Cited by 113
Remnant lipoproteins as therapeutic targets
Havel, R. J. (2000) · Current Opinion in Lipidology · doi:10.1097/00041433-200012000-00008 · Cited by 107
Apolipoprotein CIII links dyslipidemia with atherosclerosis
Kawakami, A., & Yoshida, M. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e607 · Cited by 98
Nakajima, K., Nagamine, T., Fujita, M., Ai, M., Tanaka, A., & Schaefer, E. J. (2014) · Advances in clinical chemistry · doi:10.1016/b978-0-12-800263-6.00003-3 · Cited by 89
Self-citationScheffer, P. G., Teerlink, T., Dekker, J. M., Bos, G., Nijpels, G., Diamant, M., Kostense, P. J., Stehouwer, C. D. A., & Heine, R. J. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.103234 · Cited by 66
van Oostrom, A. J. H. H. M., van Wijk, J. P. H., & Cabezas, M. C. (2004) · Drugs · doi:10.2165/00003495-200464002-00004 · Cited by 78
Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813942 · Cited by 69
Atherogenic postprandial remnant lipoproteins; VLDL remnants as a causal factor in atherosclerosis
Nakajima, K., & Tanaka, A. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2017.12.039 · Cited by 57
Self-citationDevelopment of a Homogeneous Assay to Measure Remnant Lipoprotein Cholesterol
Miyauchi, K., Kayahara, N., Ishigami, M., Kuwata, H., Mori, H., Sugiuchi, H., Irie, T., Tanaka, A., Yamashita, S., & Yamamura, T. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2007.092296 · Cited by 56
Postprandial Remnant-like Lipoproteins in Hypertriglyceridemia1
Ooi, T. C., Cousins, M., Ooi, D. S., Steiner, G., Uffelman, K. D., Nakajima, K., & Simo, I. E. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7627 · Cited by 55
Self-citationPackard, C. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00994-z · Cited by 52
Update on the laboratory investigation of dyslipidemias
Ramasamy, I. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.01.015 · Cited by 50
Karpe, F. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00700-0 · Cited by 50
Wang, T., Nakajima, K., Leary, E. T., Warnick, G. R., Cohn, J. S., Hopkins, P. N., Wu, L. L., Cilla, D. D., Zhong, J., & Havel, R. J. (1999) · PubMed · Cited by 50
Self-citationMarcoux, C., Hopkins, P. N., Wang, T., Leary, E. T., Nakajima, K., Davignon, J., & Cohn, J. S. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33455-6 · Cited by 43
Self-citationMarcoux, C., Tremblay, M., Fredenrich, A., Davignon, J., & Cohn, J. S. (2001) · Metabolism · doi:10.1053/meta.2001.19452 · Cited by 45
Self-citationOkazaki, M., Usui, S., Tada, N., Nakano, T., & Nakajima, K. (2000) · Clinica Chimica Acta · doi:10.1016/s0009-8981(00)00213-8 · Cited by 41
Self-citationHirany, S., O’Byrne, D., Devaraj, S., & Jialal, I. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.5.667 · Cited by 39
Waterworth, D. M., Hubacek, J. A., Pitha, J., Kovar, J., Poledne, R., Humphries, S. E., & Talmud, P. J. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32016-2 · Cited by 38
Koba, S., Hirano, T., Murayama, S., Kotani, T., Tsunoda, F., Iso, Y., Ban, Y., Kondo, T., Suzuki, H., & Katagiri, T. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00245-4 · Cited by 35
Nakano, T., Tanaka, A., Okazaki, M., Tokita, Y., Nagamine, T., & Nakajima, K. (2011) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/acb.2010.010193 · Cited by 29
Self-citationChapman, M. J., Packard, C. J., Björnson, E., Ginsberg, H. N., & Borén, J. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120529 · Cited by 39
Shirakawa, T., Nakajima, K., Shimomura, Y., Kobayashi, J., Stanhope, K. L., Havel, P. J., Machida, T., Sumino, H., & Murakami, M. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.07.020 · Cited by 29
Self-citationThe VLDL receptor plays a key role in the metabolism of postprandial remnant lipoproteins
Nakajima, K., Tokita, Y., Tanaka, A., & Takahashi, S. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.05.004 · Cited by 34
Self-citationCampos, E., Kotite, L., Blanche, P., Mitsugi, Y., Frost, P. H., Masharani, U., Krauss, R. M., & Havel, R. J. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30142-5 · Cited by 28
Therapeutic Effects of Fibrates in Postprandial Lipemia
Kolovou, G. D., Kostakou, P. M., Anagnostopoulou, K. K., & Cokkinos, D. V. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200808040-00004 · Cited by 29
Sato, K., Okajima, F., Miyashita, K., Imamura, S., Kobayashi, J., Stanhope, K. L., Havel, P. J., Machida, T., Sumino, H., Murakami, M., et al. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.06.020 · Cited by 26
Self-citationPlasma triglyceride-rich lipoprotein remnants as a risk factor of ‘Pokkuri disease’
Takeichi, S., Nakajima, Y., Yukawa, N., Saito, T., Seto, Y., Huang, X.-L., Kusakabe, T., Jin, Z.-B., Hasegawa, I., Nakano, T., et al. (2001) · Legal Medicine · doi:10.1016/s1344-6223(01)00010-4 · Cited by 25
Self-citationJaveshghani, D., Schiffrin, E. L., Sairam, M. R., & Touyz, R. M. (2009) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2009.07.002 · Cited by 27
Nakajima, K., Nakajima, Y., Takeichi, S., & Fujita, M. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.08.057 · Cited by 23
Self-citationTsunoda, F., Koba, S., Hirano, T., Ban, Y., Iso, Y., Suzuki, H., Geshi, E., & Katagiri, T. (2004) · Circulation Journal · doi:10.1253/circj.68.1165 · Cited by 23
Remnant-like particles cholesterol is higher in diabetic patients with coronary artery disease
Higashi, K., Ito, T., Nakajima, K., Yonemura, A., Nakamura, H., & Ohsuzu, F. (2001) · Metabolism · doi:10.1053/meta.2001.27193 · Cited by 18
Self-citationZhang, B., Böttcher, A., Imaizumi, S., Noda, K., Schmitz, G., & Saku, K. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.03.004 · Cited by 16
Zhang, B., Maeda, N., Okada, K., Tatsukawa, M., Sawayama, Y., Matsunaga, A., Kumagai, K., Miura, S., Nagao, T., Hayashi, J., et al. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.09.005 · Cited by 16
Nakano, T., Tokita, Y., Nagamine, T., Tanaka, A., Okazaki, M., Yatsuzuka, S.-I., Tamei, N., Shimomura, Y., Ando, Y., Akamatsu, S., et al. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.09.040 · Cited by 14
Self-citationGüldür, T., Bayraktar, N., Kaynar, Ö., G. Beker, Koçer, M., & Özcan, H. (2007) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp.2007.18.1.21 · Cited by 11
Takeichi, S., Nakajima, Y., Yukawa, N., Fujita, M., Saito, T., Satoh, F., Seto, Y., Kusakabe, T., Jin, Z.-B., Hasegawa, I., et al. (2004) · Clinica Chimica Acta · doi:10.1016/j.cccn.2003.12.031 · Cited by 10
Self-citationChan, D. C., Watts, G. F., Ng, T. W., Uchida, Y., Sakai, N., Yamashita, S., & Barrett, P. H. R. (2005) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2005.05.009 · Cited by 9
Zaratin, A. C. M., Bertolami, M. C., Faludi, A. Á., Rocha, J. C., Nunes, V. S., Nakandakare, E. R., Quintão, E. C. R., & de Faria, E. C. (2001) · Clinica Chimica Acta · doi:10.1016/s0009-8981(00)00431-9 · Cited by 7
Duvillard, L., CASLAKE, M. J., Petit, J., Vergès, B. L., Gambert, P., & Packard, C. J. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.11.026 · Cited by 8
Hidaka, H., Tozuka, M., Meyer, B. J., Yamauchi, K., Sugano, M., Nakabayashi, T., & Katsuyama, T. (2003) · PubMed · Cited by 9
Saito, M., Eto, M., & Kaku, K. (2002) · Metabolism · doi:10.1053/meta.2002.34014 · Cited by 8
Nakajima, K. (2014) · Clinical & Experimental Thrombosis and Hemostasis · doi:10.14345/ceth.14013 · Cited by 5
Self-citationNakajima, Y., Takeichi, S., Osawa, M., Nakajima, K., Nakano, T., & Fujita, M. (2006) · PubMed · Cited by 3
Self-citationA Proposal of The New Mechanism on Remnant Lipoprotein Formation and Clearance after Food Intake
Nakajima, K., & Tanaka, A. (2017) · Journal of Aging Science · doi:10.4172/2329-8847.1000173 · Cited by 1
Self-citationLipoproteins and Hyperlipoproteinemia: Links to Gout
Hsu, T. C. (2012) · Otago University Research Archive (University of Otago)
Usuki, Y., & Mokuno, H. (2000) · Juntendō Igaku/Juntendo igaku · doi:10.14789/pjmj.46.48
Isolation and Detection of Serum Lp-X by Immunoaffinity Separation Method
Nakajima, K., Nakano, T., Nakazato, K., & Nagamine, T. (2015) · Journal of Clinical and Laboratory Investigation Updates · doi:10.14205/2310-9556.2015.03.01.1
Self-citationStanner, S., Coe, S., & Frayn, K. N. (2018) · Wiley eBooks · doi:10.1002/9781118829875.refs
Frayn, K. N., & Stanner, S. A. (2005) · Wiley eBooks · doi:10.1002/9780470774663.refs
Hypertriglyceridemia: diagnostic issues, therapeutic strategies
Bakaleiko, V. V., Reutova, O. V., Алиева, М. С., Baratashvili, G. G., Kostareva, A. A., & Alieva, A. S. (2024) · Russian Journal for Personalized Medicine · doi:10.18705/2782-3806-20244-3-194-205 · Cited by 1
Metadata
- Authors
- Marcoux, C., Tremblay, M., Nakajima, K., Davignon, J., & Cohn, J. S.
- Affiliations
- Montreal Clinical Research Institute (CA)
- Otsuka (United States) (US)
- Corresponding author
- Cohn, Jeffrey S.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 1999-04
- Volume
- 40
- Issue
- 4
- Pages
- 636-647
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2363979887
- Cited by
- 61
- References
- 55
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2019: 1 · 2018: 3 · 2017: 1 · 2016: 1 · 2015: 1 · 2014: 3 · 2012: 1
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 7826 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- remnant-like particles, triglyceride-rich lipoproteins, type III hyperlipoproteinemia, type IV hyperlipoproteinemia, hypertriglyceridemia, apolipoprotein E, apolipoprotein C-III, lipoprotein composition, atherogenic lipoproteins
- MeSH terms
- Adult, Apolipoproteins B, Apolipoproteins C, Apolipoproteins E, Cholesterol, Humans, Hyperlipoproteinemia Type III, Hyperlipoproteinemia Type IV, Lipoproteins, Lipoproteins, VLDL, Male, Middle Aged, Particle Size, Triglycerides, Electrophoresis, Gel, Two-Dimensional, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.